Psychedelic Virtual Reality

This observational, case-crossover trial (n=15) will evaluate the subjective experience of a novel virtual reality programme (VRP), DeepDream, in comparison to a standard dose of psychedelics.

Conducted by Yale University and led by Dr Anahita Bassir Nia, the study aims to assess whether DeepDream can replicate the subjective effects of psychedelics using tools such as the Altered States of Consciousness Rating Scale, the Mystical Experience Questionnaire, and the Ego-Dissolution Inventory. Additionally, the study will compare DeepDream to other VR modalities designed to mimic psychedelic experiences and will assess the incidence of adverse effects, including virtual reality sickness and musculoskeletal discomfort. Healthy adult volunteers (aged 21–65) will participate, with data collection spanning from February to August 2025.

Trial Details

The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.

Trial Number NCT06581263

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.